Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis

Eiji Matsuura, Kazuko Kobayashi, Masako Tabuchi, Luis R. Lopez

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and foam cell formation. Recent findings suggested that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) in the intima of atherosclerotic lesions. Autoantibodies against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) and significantly correlate with arterial thrombosis. IgG autoantibodies having similar specificity emerged spontaneously in non-immunized NZW × BXSB F1 mice, an animal model of APS, and a monoclonal autoantibody (WB-CAL-1; IgG2a) against complexed β2GPI (oxLDL/β2GPI complexes) was derived from the same mice. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages. This observation strongly suggests that such IgG autoantibodies are pro-atherogenic. In contrast, IgM anti-oxLDL natural antibodies found in the atherosclerosis-prone mice (ApoE-/- and LDL-R-/- mice) have been proposed to be anti-atherogenic (protective). The presence of IgG anti-oxLDL antibodies in humans has been documented in many publications but their exact clinical significance remains unclear. In this article, we review recent progress in our understanding of the mechanisms involved in oxidation of LDL, formation of oxLDL complexes, and antibody mediated-immune regulation of atherogenesis.

Original languageEnglish
Pages (from-to)466-486
Number of pages21
JournalProgress in Lipid Research
Volume45
Issue number6
DOIs
Publication statusPublished - Nov 2006

Fingerprint

LDL Lipoproteins
Atherosclerosis
Glycoproteins
Autoantibodies
Antiphospholipid Syndrome
Antibodies
Immunoglobulin G
oxidized low density lipoprotein
Foam Cells
Apolipoproteins E
Macrophages
Systemic Lupus Erythematosus
C-Reactive Protein
Publications
Thrombosis
Foams
Animal Models
Animals
Lipids
Oxidation

Keywords

  • β-glycoprotein I
  • Antiphospholipid antibody
  • Antiphospholipid syndrome
  • Atherosclerosis
  • Foam cell formation
  • Oxidized LDL

ASJC Scopus subject areas

  • Cell Biology

Cite this

Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. / Matsuura, Eiji; Kobayashi, Kazuko; Tabuchi, Masako; Lopez, Luis R.

In: Progress in Lipid Research, Vol. 45, No. 6, 11.2006, p. 466-486.

Research output: Contribution to journalArticle

@article{2530df09282246d59c99f1fe8c51275a,
title = "Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis",
abstract = "Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and foam cell formation. Recent findings suggested that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) in the intima of atherosclerotic lesions. Autoantibodies against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) and significantly correlate with arterial thrombosis. IgG autoantibodies having similar specificity emerged spontaneously in non-immunized NZW × BXSB F1 mice, an animal model of APS, and a monoclonal autoantibody (WB-CAL-1; IgG2a) against complexed β2GPI (oxLDL/β2GPI complexes) was derived from the same mice. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages. This observation strongly suggests that such IgG autoantibodies are pro-atherogenic. In contrast, IgM anti-oxLDL natural antibodies found in the atherosclerosis-prone mice (ApoE-/- and LDL-R-/- mice) have been proposed to be anti-atherogenic (protective). The presence of IgG anti-oxLDL antibodies in humans has been documented in many publications but their exact clinical significance remains unclear. In this article, we review recent progress in our understanding of the mechanisms involved in oxidation of LDL, formation of oxLDL complexes, and antibody mediated-immune regulation of atherogenesis.",
keywords = "β-glycoprotein I, Antiphospholipid antibody, Antiphospholipid syndrome, Atherosclerosis, Foam cell formation, Oxidized LDL",
author = "Eiji Matsuura and Kazuko Kobayashi and Masako Tabuchi and Lopez, {Luis R.}",
year = "2006",
month = "11",
doi = "10.1016/j.plipres.2006.05.001",
language = "English",
volume = "45",
pages = "466--486",
journal = "Progress in Lipid Research",
issn = "0163-7827",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis

AU - Matsuura, Eiji

AU - Kobayashi, Kazuko

AU - Tabuchi, Masako

AU - Lopez, Luis R.

PY - 2006/11

Y1 - 2006/11

N2 - Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and foam cell formation. Recent findings suggested that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) in the intima of atherosclerotic lesions. Autoantibodies against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) and significantly correlate with arterial thrombosis. IgG autoantibodies having similar specificity emerged spontaneously in non-immunized NZW × BXSB F1 mice, an animal model of APS, and a monoclonal autoantibody (WB-CAL-1; IgG2a) against complexed β2GPI (oxLDL/β2GPI complexes) was derived from the same mice. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages. This observation strongly suggests that such IgG autoantibodies are pro-atherogenic. In contrast, IgM anti-oxLDL natural antibodies found in the atherosclerosis-prone mice (ApoE-/- and LDL-R-/- mice) have been proposed to be anti-atherogenic (protective). The presence of IgG anti-oxLDL antibodies in humans has been documented in many publications but their exact clinical significance remains unclear. In this article, we review recent progress in our understanding of the mechanisms involved in oxidation of LDL, formation of oxLDL complexes, and antibody mediated-immune regulation of atherogenesis.

AB - Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and foam cell formation. Recent findings suggested that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) in the intima of atherosclerotic lesions. Autoantibodies against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) and significantly correlate with arterial thrombosis. IgG autoantibodies having similar specificity emerged spontaneously in non-immunized NZW × BXSB F1 mice, an animal model of APS, and a monoclonal autoantibody (WB-CAL-1; IgG2a) against complexed β2GPI (oxLDL/β2GPI complexes) was derived from the same mice. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages. This observation strongly suggests that such IgG autoantibodies are pro-atherogenic. In contrast, IgM anti-oxLDL natural antibodies found in the atherosclerosis-prone mice (ApoE-/- and LDL-R-/- mice) have been proposed to be anti-atherogenic (protective). The presence of IgG anti-oxLDL antibodies in humans has been documented in many publications but their exact clinical significance remains unclear. In this article, we review recent progress in our understanding of the mechanisms involved in oxidation of LDL, formation of oxLDL complexes, and antibody mediated-immune regulation of atherogenesis.

KW - β-glycoprotein I

KW - Antiphospholipid antibody

KW - Antiphospholipid syndrome

KW - Atherosclerosis

KW - Foam cell formation

KW - Oxidized LDL

UR - http://www.scopus.com/inward/record.url?scp=33748316789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748316789&partnerID=8YFLogxK

U2 - 10.1016/j.plipres.2006.05.001

DO - 10.1016/j.plipres.2006.05.001

M3 - Article

C2 - 16790279

AN - SCOPUS:33748316789

VL - 45

SP - 466

EP - 486

JO - Progress in Lipid Research

JF - Progress in Lipid Research

SN - 0163-7827

IS - 6

ER -